{"name":"Neuron23 Inc.","slug":"neuron23-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOcENvS2pMT0ZsUHdZVi1PY3B3QWQyV0tvMlV6QkpNR1hOQ29VRkZUaHVoSVRsLURpaDR2dURkWllBQXZ5b1ZPYlZsSS1NeWJmOElFWDdIbXJVU0F3emxBX0VDSjlkVDZXWU1ZU3ZERklXZXJGUjlCeGZSbFNYRzdJU0pPM25WRV9wQkcxZEZiZ3Bfd1EwejR4SmlqMzZGYXV1YVhEckJUa1NIcnk0?oc=5","date":"2025-07-31","type":"pipeline","source":"The Business Journals","summary":"Neuron23 CEO is digging deeper in Parkinson's, MS drug hunt - San Francisco Business Times - The Business Journals","headline":"Neuron23 CEO is digging deeper in Parkinson's, MS drug hunt - San Francisco Business Times","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE84ZTJmTmRESWdZMHh0TWNDbmVMbUFKbF9EelVSbUttNldwdVdkVlNMZk95OHVpamg2MmdKME1sZERyU1B5OGQ0eFF0UmdaVUFVc0dr?oc=5","date":"2025-06-24","type":"pipeline","source":"FirstWord Pharma","summary":"Neuron23 bags $96.5M to advance targeted Parkinson's therapy - FirstWord Pharma","headline":"Neuron23 bags $96.5M to advance targeted Parkinson's therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxOc3JXQnpFYlNXYVRYS0VQdzJfMFhmUlg5elJhM0pMRWdTM3Z5Zk8xMzVpREZZZ0RQcEplMHhobzY0N2RzTXRJeEZrSnV1Z3BNMEZmZ256cEVGbVZUaGZiRU4yUWtjbWQzQTVEbjhqNTNHYVZKT0paSlhhUExaNjRhYkNRLUZvWUJEaXFfcThCaEpsLUVTOU1WaE83cUcxVFctZkRrRnVxdi1lRHJDekExZjBxZWRLNDRFczd1VmlqUVV6eHNaOHBOSGRYa1ZoeDkxT05Ua1p1YkV5SFlEU245VjRZSU9YNHNOMHFUY2hTUjI2dHp2dVFVRFNzQkhVQVd0RDhIS3pGRzZTZUF3bTNidzJoQWtxNE16Wkg4RUgxVmsydVl4dHlFbDZQUVplR05sbXdISEphLU1ENlk?oc=5","date":"2025-06-24","type":"trial","source":"businesswire.com","summary":"Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease - businesswire.com","headline":"Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOeE5CRkYzQzJNV2JCZm9GXzBrS3hfeGNSeEJqdkNUa180X2cydG4wLWRxZ1VNT1lhRlZBWG9odW03TEp3LVBUU3Q1emZFclliZDlOZExpenJ1MXRoai1xbkd4QVJxN2tVRWZLVVlYOTBSTzMzSEJVRVpMV19vVUllSnE1ZDZPajg3WTN3RW1QSFdJWmgzaUFJMUhBeHJfMlc2M2VKN2dPRWp4MVVxb3NCUXRnWFdlXzFkOHE2UElaSmFaazR5TzFjRU1BOTBOYUtoZmdqYjgtYmd4b2xsZ3RuMlIxSQ?oc=5","date":"2025-05-09","type":"pipeline","source":"The Business Journals","summary":"San Francisco Business Times Influential Women: Nancy Stagliano, Neuron23 Inc. - San Francisco Business Times - The Business Journals","headline":"San Francisco Business Times Influential Women: Nancy Stagliano, Neuron23 Inc. - San Francisco Business Times","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQTnVZQmZXdUtpNl9qVm5BVnNOZ24wVGY0d0RDeWZRS1FoaXFjQlFyYkVnekJtdy1nMExzc0FIQVU0VThYUzZZTk5zYXJ6WDQ4cjhoRWJzVUxDb3h2cUFDcVdWSFFSWkJRX2pFRjhxcF9kcV9tYnZzS1Z0UUpySElQT3ZuQUF0UU9sc2N2Vjk3YUl2ZElVUXNHQnVQTHk2NU51SlVwQkRHYUQ0QThyck1tUjB1RXhBaWx1NUg2OWZ5WDVxZWVnT3o5Sm9tY05aU3UyRWJyc2VKWTl1MWVJQ2NsRXYtbEJrQ0VIMnB2ZGJR?oc=5","date":"2024-11-19","type":"trial","source":"businesswire.com","summary":"Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial - businesswire.com","headline":"Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPMmwwd1VCMlBROXhYVGpCUjZkb3pnOE83a3hjcDVXYUJDdzRXQ05vRTI0aDFudy1pN1ZQMlhkczZzUXFZQXJtZFVuSUlwbFhYUDJGakFxX2wwbUowRS1KMy15YmRpRW8tZWhjY1djZS16Ykt6a0dBLXdEWTJKS2FBX21TRkctcTEyT0NOTFVNZzNHaTN2WDRXWlpxWWEtc3pLNW84eG5CTHJwaGlmLXBhX1B0cw?oc=5","date":"2024-11-19","type":"trial","source":"BioSpace","summary":"Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease - BioSpace","headline":"Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNd3ZOVDlwNm9YYmV3QThQZFVTRXdna3RjUE9uWVlSTm5aOG5XZzJRMUZPVkt3cml6M2paZWRxTkZsdHpJSnJYWnRaWkM2Q2RldnlaVzdwV29GN1pRY1IxeV9pWG9FNDZLVF9LeEVIWHFvc0xpdE1hOEVOMFBSRE5YLXQxWFR2UkZOZndOell3VlNybFFONUxpM1JFYmF2OHNGQ1lzNk9qdw?oc=5","date":"2023-11-29","type":"pipeline","source":"Timmerman Report","summary":"The Final Frontier of Brain Science: Nancy Stagliano on The Long Run - Timmerman Report","headline":"The Final Frontier of Brain Science: Nancy Stagliano on The Long Run","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPNDRyQ29PZzFuOU5Oa0pQdFhtdW1FVXFLUUJ1eEdxb25WVnhlLS0xNW94NlljUlVzLTVpX1ZIV2c4bUVuVnVkZXhSejBJdGpzdm5LWnhsTlNqVzBxVlJQZlpuTDBHaFNaLXBfR1VzdkF6UnZEdEhNc3lyX2pOd3Y3eA?oc=5","date":"2023-06-05","type":"trial","source":"pharmaphorum","summary":"Biogen pulls the plug on late-stage Parkinson’s trial - pharmaphorum","headline":"Biogen pulls the plug on late-stage Parkinson’s trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPUk9aNHYwc0U3MzRjNjBEX1NHdEgzZmFGdlVpVThkODF5Ujg0c3FPT1JWMjJQNldCc2NpalZLUTJwOWJ1ZXh1bEhHU1c5ZEthRFA5N2E4Zzl1TE9qZmotSXdDZnZEWHkxSnBxaXJOMWZlMS00b2dqYk91b0ljVUF5dnJBdzFfRklBc01JZUFBUDg0cmY0RGtPVjBlcThhYXdIcDJoSk8xNnJVY3gxLVJsYUxveC03U01tOHRwTlkwZXE2OUZjVzB3UTl3?oc=5","date":"2022-03-30","type":"pipeline","source":"BioSpace","summary":"Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease - BioSpace","headline":"Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNM3UxU1pVZFNQWERJZG81OEJDeURZZ1NvVUozXzllOFMtaUVjSUdVUDRGRHJVQjRVaWMyVTY5anRCWTFKWU05VjZwRVdhUmwxQmNXVkt1c0VTSEdacFhYc3JaOUJvTkJfVkNhbWRkU3ZsVTFld2JoWGpOYXNWdGFXZG1MNWpacE9CTy01cGFRUXJMQm1Ub1pvRkZVNVZXMWRYLUFvSGNjSmhGS0R4a1E?oc=5","date":"2022-03-30","type":"pipeline","source":"MedCity News","summary":"Vying to best bigger rivals in Parkinson’s, Neuron23 nabs $100M to reach clinic - MedCity News","headline":"Vying to best bigger rivals in Parkinson’s, Neuron23 nabs $100M to reach clinic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQNkdBZFFqd25QdU5DcndHVm8ycVlzNldwczhMcERqVDNUcGFzZ3JuM20yX2pWdmlCbUYzTUQtbjNFWFU3NC1BV1d1dDlpclV0akR1SndseG1qb2syOUdyTTdPaTYzQ2J0Zk90cjU0VWJTMWs4ZU5KTDV3elBQdVV4aXBVTkp2aUxHSFR4b1JvaG5pV19hYVhHY1llUW5vU0tCNFphR09PWFFtS0wwOHVjLXlrZEpHVFNiTGc0UE5PNVV6ZUR1eEhUSzF0WldqLTBKY3pUSkNpMkZXT082V1RjQUV6WVJ0bTFFWVRybVNOLTdERnE0OGVJTFAtNDNPRk9MWm9SYWxYdldtaDFw?oc=5","date":"2020-12-16","type":"deal","source":"prnewswire.com","summary":"Neuron23™ Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group - prnewswire.com","headline":"Neuron23™ Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmi","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}